Kisspeptin was discovered back in 1996 for its activity as a metastasis inhibitor in melanoma cell lines. It has since been found to be a modulator of the mammalian reproductive axis. As such, it has been studied in a few clinical trials related to hypogonadism, reproduction and fertility, men’s libido, and more.
Kisspeptin is a peptide family that originates from the KISS1/kiss1 gene. Kisspeptin acts on the kisspeptin receptor to regulate the reproductive axis via stimulation of hypothalamic gonadotrophin releasing hormone (GnRH) release. Via its mechanism, it may have gonadal effects and interactions with certain metabolic pathways. Its activity makes it a potential candidate for treating infertility and sexual dysfunction (1).
Research supports the fact that kisspeptin plays a key role in reproduction. In fact, early human studies have shown that administration of kisspeptin administration can activate gonadotrophin release in healthy adults as well as in individuals struggling with certain types of infertility (3).
Additionally, animal models have shown that kisspeptin can also play a role in sexual motivation and erections in men. Research indicates that kisspeptin administration can increase limbic activity when responding to sexual stimuli. One study included 32 men randomized to receive either kisspeptin or placebo. Those treated with kisspeptin showed that kisspeptin modulated brain activity in response to viewing sexual videos. Additionally, the study showed improvements in penile tumescence and behavioral measures related to sexual desire (4).
The mechanism of kisspeptin is fairly well-characterized, and through stimulating GnRH, can ultimately impact sex hormones. Most of the current, real-world evidence lies in its ability to become a fertility treatment. Other emerging potentials include hypogonadism, where men with low testosterone may see benefit, as well as with improving sexual function. However, there are no large, placebo-controlled trials that have validated these potential effects and fully established its safety and efficacy profile.
Kisspeptin is not approved by the US Food and Drug Administration (FDA) and thus has no approved indication within the US. It also is not presently included on the FDA-approved bulk substance lists, and thus it is not legal to compound under 503A/503B. Thus, kisspeptin is not held to the same quality, safety, and efficacy standards of approved drugs. There could potentially be variability in manufacturing and sterility concerns, especially as an injectable.
The FDA has indicated that compounded kisspeptin can carry the risk of immunogenicity with certain routes of administration. Additionally, there could be peptide-related impurities and API characterization (5).
Another point to consider is kisspeptin’s mechanism. By stimulating GnRH, it can cause a ripple effect throughout the whole reproductive hormone axis, ultimately leading to increases in sex hormones like estrogen and testosterone. This could lead to hormonal imbalance.
In summary, kisspeptin shows promise in some conditions related to the reproductive system, such as with fertility and libido. However, there is limited clinical data and no FDA approval, leading to quality and safety concerns when used outside of research settings.
The information provided in this article is for educational purposes only and is not intended as medical advice. Many peptides are not FDA-approved for human use outside of limited clinical contexts. These compounds are often obtained through unregulated sources that lack quality control. Studies suggest 30–65% of products may be contaminated or mislabeled, with risks including endotoxins, heavy metals, and incorrect sequences. At Weight Loss & Vitality, we focus on evidence-based, medically supervised therapies.
As of April 21, 2026, regulatory status for many peptides remains under review and may change as additional data and guidance become available.
As peptide therapies gain attention, maintaining proper oversight remains critical. Our medically supervised peptide programs are designed to prioritize both effectiveness and patient safety.
References
